Skip to main content
. 1998 Nov;72(11):8943–8951. doi: 10.1128/jvi.72.11.8943-8951.1998

TABLE 1.

Antigenic characterization of glycoproteins

Antigena Recognition of gp120 by the following ligand (OD)b:
QC256 sCD4 39.13g 38.1a
Mock 0.05 ND ND 0.04
LAI 1.45 ND ND 1.43
605.22 1.57 0.74 0.90 1.45
605.24 1.50 1.34 1.41 1.47
605.25 1.47 0.07 0.09 1.41
605.49 1.57 1.36 1.51 1.40
605.51 1.65 1.14 1.32 1.60
605.54 1.56 1.35 1.42 1.52
605.55 1.61 0.07 0.10 1.56
605.56 1.61 1.31 1.50 1.62
605.57 1.51 0.93 1.37 1.40
605.58 1.61 0.07 0.07 1.54
605.59 1.66 1.35 1.45 1.58
612.30 1.52 1.05 1.42 1.46
612.28 1.62 1.30 1.35 1.47
612.31 1.55 1.24 1.39 1.55
612.74 1.53 0.25 1.04 1.43
612.75 1.56 1.35 1.52 1.52
612.77 1.40 0.08 0.14 1.37
612.78 1.61 1.27 1.40 1.50
612.79 1.51 1.30 1.43 1.56
612.82 1.36 0.07 0.09 1.33
a

Mock indicates cell-free supernatant from transfection of a pCDNA3 clone with no gp120 insert. LAI indicates cell-free supernatant from transfection of a pCDNA3 clone carrying the HIV strain LAI BH10 sequence. Clone designations are derived from the clinic number. Clones with the 605 prefix were derived from plasma at day 7, and clones with the 612 prefix were derived from day-11 plasma. 

b

Results are shown as the mean optical density (OD) at 450 nm for three replicate samples. ND, not determined. QC256 was tested at a final serum dilution of 1/1,000, and sCD4 and MAbs 39.13g and 38.1a were used at 5 μg/ml.